Articles

What do we need to tell our patients about preventing the risk for death?

Psychological health, access to care, expanded and personalized treatment options and the tracking of hypoglycemia emphasized.

New recommendation based on results from two large clinical trials for patients with diabetes and CVD.

Clinically significant hypoglycemia redefined, bariatric surgery renamed.

Guest Post by David Kliff, Diabetic Investor
Dexcom (NASDAQ: DXCM) received FDA approval for non-adjunctive claim.

Study data show fasting glucose concentrations of at least 100 mg/dL (5.6 mmol/L) or an HbA1c of at least 5.7% (39 mmol/mol) were determining factors.

Possible future of diabetes management for the masses may have finally arrived, but will patients use the programs and will insurers pay?

The results from a new study show that risk increased in women with an early HbA1c of at least 5.9% regardless of a gestational diabetes diagnosis later in pregnancy.

Liraglutide, on top of stable renin angiotensin system (RAS)-inhibition, is associated with significant reduction in albuminuria among patients with type 2 diabetes and persistent microalbuminuria.

Study offers at least partial explanation for opposing findings between previous observational studies.